The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABBV | +13.46% | +170.8% | +22.05% | +950% |
| S&P | +13.96% | +91.24% | +13.85% | +382% |
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
A list of high-yielding dividend stocks to consider buying now.
Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $15.78B | 9.1% |
| Gross Profit | $10.43B | 1.6% |
| Gross Margin | 66.12% | -4.9% |
| Market Cap | $409.03B | 17.3% |
| Market Cap / Employee | $7.44M | 0.0% |
| Employees | 55K | 10.0% |
| Net Income | $178.00M | -88.5% |
| EBITDA | $6.67B | 10.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.63B | -22.4% |
| Accounts Receivable | $12.77B | 11.3% |
| Inventory | 4.9K | 11.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $62.97B | 7.6% |
| Short Term Debt | $5.77B | -54.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.69% | -1.9% |
| Return On Invested Capital | 9.75% | -1.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $6.64B | 27.8% |
| Operating Free Cash Flow | $7.02B | 29.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 74.30 | 89.34 | 88.34 | 174.71 | 153.67% |
| Price to Book | 52.06 | 111.23 | 230.88 | -2234.94 | -4443.78% |
| Price to Sales | 5.58 | 6.47 | 5.64 | 6.88 | 9.17% |
| Price to Tangible Book Value | -3.27 | -4.03 | -3.55 | -4.40 | 9.70% |
| Price to Free Cash Flow TTM | 46.18 | 88.25 | 47.64 | 50.12 | -32.88% |
| Enterprise Value to EBITDA | 55.60 | 72.24 | 49.81 | 70.96 | 3.81% |
| Free Cash Flow Yield | 2.2% | 1.1% | 2.1% | 2.0% | 48.99% |
| Return on Equity | 61.9% | 88.2% | 112.9% | 138.5% | 147.09% |
| Total Debt | $67.84B | $69.89B | $70.48B | $68.74B | -3.29% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
